Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CCR1 | P32246 | 2/20 | 0.55 |
| ▸ | CCR3 | P51677 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032891 | 0.93 | SMN1; SMN2 (0.60) | SIGMAR1MEN1KMT2ACCR1CCR3 | |
| SCHEMBL4031280 | 0.86 | TSHR (0.58) | SIGMAR1MEN1KMT2ACCR1CCR3 | |
| SCHEMBL4031536 | 0.86 | TSHR (0.58) | SIGMAR1MEN1KMT2ACCR1CCR3 | |
| SCHEMBL4213798 | 0.83 | MEN1 (0.48) | SIGMAR1MEN1KMT2ACCR1CCR3 | |
| SCHEMBL4036379 | 0.83 | MEN1 (0.54) | SIGMAR1MEN1KMT2ACCR1CCR3 | |
| SCHEMBL4036380 | 0.83 | MEN1 (0.54) | SIGMAR1MEN1KMT2ACCR1CCR3 | |
| SCHEMBL4031705 | 0.82 | SMN1; SMN2 (0.72) | SIGMAR1KMT2ATSHRHTTATM | |
| SCHEMBL4032532 | 0.82 | ATM (0.55) | SIGMAR1MEN1KMT2ACCR1CCR3 | |
| SCHEMBL4032572 | 0.81 | TSHR (0.58) | SIGMAR1KMT2ACCR3MCHR1TSHR | |
| SCHEMBL4032329 | 0.80 | KMT2A (0.49) | KMT2ACCR3TSHRHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | claimed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | SIGMAR1 126/4885MEN1 4130/4885KMT2A 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.